| On model-based time trend adjustments in platform trials with non-concurrent controls MB Roig, P Krotka, CF Burman, E Glimm, SM Gold, K Hees, P Jacko, ... BMC medical research methodology 22 (1), 228, 2022 | 34 | 2022 |
| Selection of composite binary endpoints in clinical trials M Bofill Roig, G Gómez Melis Biometrical Journal 60 (2), 246-261, 2018 | 17 | 2018 |
| Platform trials and the future of evaluating therapeutic behavioural interventions SM Gold, M Bofill Roig, JJ Miranda, C Pariante, M Posch, C Otte Nature Reviews Psychology 1 (1), 7-8, 2022 | 15 | 2022 |
| On the use of non-concurrent controls in platform trials: A scoping review M Bofill Roig, C Burgwinkel, U Garczarek, F Koenig, M Posch, Q Nguyen, ... Trials 24 (1), 408, 2023 | 10 | 2023 |
| A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components M Bofill Roig, G Gómez Melis Statistics in medicine 38 (11), 1935-1956, 2019 | 9 | 2019 |
| Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment MB Roig, GG Melis, M Posch, F Koenig Biostatistics 25 (1), 237-252, 2024 | 5 | 2024 |
| Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL F Koenig, C Spiertz, D Millar, S Rodríguez-Navarro, N Machín, ... Eclinicalmedicine 67, 2024 | 5 | 2024 |
| Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis G Semmler, B Scheiner, L Balcar, R Paternostro, B Simbrunner, M Pinter, ... Alimentary Pharmacology & Therapeutics 58 (1), 71-79, 2023 | 5 | 2023 |
| Commentary: Two approaches to analyze platform trials incorporating non-concurrent controls with a common assumption M Bofill Roig, F König, E Meyer, M Posch Clinical Trials 19 (5), 502-503, 2022 | 5 | 2022 |
| The online closure principle L Fischer, M Bofill Roig, W Brannath The Annals of Statistics 52 (2), 817-841, 2024 | 4 | 2024 |
| A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma L Balcar, B Scheiner, CAM Fulgenzi, A D’Alessio, K Pomej, MB Roig, ... JHEP reports 6 (2), 100982, 2024 | 4 | 2024 |
| An Adaptive-Discard-Graph for online error control L Fischer, MB Roig, W Brannath arXiv preprint arXiv:2301.11711, 2023 | 3 | 2023 |
| An exhaustive ADDIS principle for online FWER control L Fischer, MB Roig, W Brannath Biometrical Journal 66 (3), 2300237, 2024 | 2 | 2024 |
| NCC: An R-package for analysis and simulation of platform trials with non-concurrent controls P Krotka, K Hees, P Jacko, D Magirr, M Posch, MB Roig SoftwareX 23, 101437, 2023 | 2 | 2023 |
| A class of two-sample nonparametric statistics for binary and time-to-event outcomes M Bofill Roig, G Gómez Melis Statistical Methods in Medical Research, 2021 | 2 | 2021 |
| Design Considerations for a Phase II platform trial in Major Depressive Disorder MM Freitag, D Zocholl, EL Meyer, SM Gold, MB Roig, H De Smedt, ... arXiv preprint arXiv:2310.02080, 2023 | 1 | 2023 |
| Optimal allocation strategies in platform trials M Bofill Roig, E Glimm, T Mielke, M Posch arXiv e-prints, arXiv: 2304.03035, 2023 | 1 | 2023 |
| Decision tool and Sample Size Calculator for Composite Endpoints M Bofill Roig, J Cortés Martínez, G Gómez Melis arXiv, arXiv: 2001.03396, 2020 | 1 | 2020 |
| Optimal allocation strategies in platform trials with continuous endpoints M Bofill Roig, E Glimm, T Mielke, M Posch Statistical Methods in Medical Research 33 (5), 858-874, 2024 | | 2024 |
| Regulatory Issues of Platform Trials: Learnings from EU‐PEARL QL Nguyen, K Hees, S Hernandez Penna, F König, M Posch, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
Martin PoschMedical University of Vienna在 meduniwien.ac.at 的电子邮件经过验证
